Drugs | Baseline | Final score | Statistical significancea | Clinical significance | Reference |
---|---|---|---|---|---|
flut/form 500/20 μg | 4.42 ± 0.89 | 5.34 ± 1.07 | P = 0.036 |  | Bodzenta-Lukaszyk et al. Resp Med 105 674-682 2011 [13] |
flut + form 500 + 24 μg | 4.57 ± 0.99 | 5.30 ± 1.00 | |||
flut/form250/10 μg | Not reported | Mean improvement of 0.8 in both treatment groups | ns | 55 % | Bodzenta-Lukaszyk et a.l Journal of Asthma 49(10), 1060-1070, 2012 [14] |
bud/form400/12 μg | 57.6 % ns | ||||
flut/form combo | 4.8 ± 1.1 | 5.5 ± 1.1 | ns | Not available | Bodzenta-Lukaszyk et al. Current Medical Research and Opinion 29, 5 579-588, 2013 [15] |
flut + form | 4.9 ± 1.2 | 5.6 ± 1.0 | |||
Tio 5 μg add on | 4.8 in all groups | Change of 0.1 points for both active treatments compared with placebo | ns | Not available | Kerstjens et al. Journal of Allergy Clin Immunol 128, 2 308-314, 2011 [16] |
Tio 10 μg add on | |||||
Plac add on | |||||
Trial 1 | Â | Â | Â | Not achieved | Kerstjens et al. New England Journal of Medicine 367:1198-1207, 2012 [17] |
Tio 5 μg/die add on | 4.6 ± 1.1 | 5.15 | Ns | ||
plac add on | 4.6 ± 1.1 | 5.1 | Ns (p < 0.05 al week 24 | ||
Trial 2 | Â | Â | |||
Tio 5 μg/die add on | 4.6 ± 1.0 | 5.1 | |||
plac add on | 4.7 ± 1.1 | 4.93 | |||
Bud/formSMART | 4.78 | 4.81 | ns | Not available – measurement of Satisfaction with Asthma Treatment Questionnaire | Louis R et al. The International Journal of Clinical Practice 63, 10 1479-1488, 2009 [18] |
Conventional best practice | 4.78 | 4.82 | |||
Tio |  | 5.58 | P = 0.01 | Not available | Peters et al. New England Journal of Medicine 363 18 1715-1726, 2010 [19] |
Double glucocorticoid | 5.43 ± 1.05 | 5.48 | P = 0.38 | ||
salm |  | 5.71 | P < 0.001 | ||
Flut fur/vil 200/25 μg | Not available | Baseline + 0.93 ± 0.065 | ns | Not available | O’Byrne et al. Eur. Resp. Journal 43 773-782, 2014 [20] |
Flut fur.200 μg |  | Baseline + 0.88 ± 0.071 | |||
Flut prop.500 μg |  | Baseline + 0.90 ± 0.068 | |||
Flut. fur/vil 100/25 μg | 5.35 | 5.85 | ns | 46 % | Woodcock et al. Chest 144(4), 1222-1229, 2013 [21] |
flut. pro/salm 250/50 μg | 5.37 | 5.79 |  | 38 % | |
salm 50 μg | 5.175 | Baseline + 0.280 | ns | Not available | Bateman et al. J. Allergy Clin Immunol128, 315-322, 2011 [22] |
tio 5 μg |  | Baseline + 0.131 | |||
plac |  | Baseline + 0.039 |  | Not available | |
Adjustable bud/form | AQLQ | AQLQ | AQLQ | AQLQ | O’Connor et al. Journal of Asthma 47 217-223, 2010 [10] |
Fixed bud/form | Not available | Not available | P < 0.04* | 66.7 % | |
Adjustable bud/form | Â | Â | Nsb | 63.0 % | |
 |  |  |  | 61.9 % | |
 |  |  |  | No clinical difference between groups |